证券代码：605116 证券简称：奥锐特 公告编号：2025-067 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 9 月 19 日 附件： 本次保荐代表人的变更不会改变相关材料中保荐机构及保荐代表人已出具 文件的结论性意见，不涉及更新保荐机构已出具的相关材料；保荐机构及保荐 代表人将继续对之前所出具的相关文件之真实性、准确性和完整性承担相应的 法律责任。 本次保荐代表人更换后，公司 2024 年向不特定对象发行可转换公司债券项 目持续督导保荐代表人为王子阳先生、王扬先生。 公司董事会对庞军先生在公司向不特定对象发行可转换公司债券持续督导 期间所做出的工作表示衷心的感谢! 王扬先生简历详见附件。 特此公告。 奥锐特药业股份有限公司董事会 奥锐特药业股份有限公司（以下简称"公司"）于近日收到国泰海通证券股 份有限公司（以下简称"国泰海通"）出具的《国泰海通证券股份有限公司关于 更换奥锐特药业股份有限公司持续督导保 ...

(一) 提前离任的基本情况 奥锐特药业股份有限公司（以下简称"公司"）董事会于 2025 年 9 月 18 日 收到公司非独立董事李金亮先生递交的书面辞职报告。李金亮先生因工作调整， 申请辞去公司第三届董事会非独立董事职务，同时辞去董事会下属专门委员会职 务。辞职后，李金亮先生仍继续担任公司全资子公司上海奥锐特生物科技有限公 司（以下简称"奥锐特生物"）执行董事。 证券代码：605116 证券简称：奥锐特 公告编号：2025-068 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于公司董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事/高级管理人员离任情况 | | 离任职务 | 离任时间 | | 原定任期到 | | 离任原因 | 是否继续在上市 公司及其控股子 | 具体职务 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | | | | 期日 | | ...

2025 年第一次临时股东大会 会议资料 奥锐特药业股份有限公司 2025 年 9 月 | | | 奥锐特药业股份有限公司 2025 年第一次临时股东大会会议资料 奥锐特药业股份有限公司 2025 年第一次临时股东大会会议议程 一、会议时间 现场会议：2025 年 9 月 26 日（星期五）下午 14：30 网络投票：2025 年 9 月 26 日（星期五）采用上海证券交易所网络投票系统， 通过交易系统投票平台的投票时间为股东大会召开当日的交易时间段，即 2025 年 9 月 26 日 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投 票时间为股东大会召开当日的 9:15-15:00。 二、现场会议地点 浙江省台州市天台县八都工业园区隆兴路 1 号 奥锐特药业公司行政大楼三 楼会议室 三、会议召集人 奥锐特药业股份有限公司董事会 四、会议主持人 公司董事长彭志恩先生 五、出席人员 3、《关于修订公司部分治理制度的议案》。 七、会议流程 1、与会人员签到； 2、大会主持人宣布会议开始，介绍本次股东大会的出席情况； 3、宣读公司 2025 年第一次临时股东大会会议须知； 4 ...

奥锐特9月18日公告，公司董事会收到公司非独立董事李金亮递交的书面辞职报告。李金亮因工作调 整，申请辞去公司第三届董事会非独立董事等职务。辞职后，李金亮仍继续担任公司全资子公司上海奥 锐特生物科技有限公司执行董事。李金亮的辞职报告自送达公司之日起生效。 ...

Market Overview - The Shanghai Composite Index is at 3852.31 points with a decline of -0.21% as of 10:32 AM, and the total trading volume of A-shares is 1,075.764 billion yuan [1] Stocks with Death Cross - A total of 152 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Songjing Co., Ltd. (688157) with a distance of -1.61% - Chunguang Technology (603657) with a distance of -1.02% - Pilin Bio (000403) with a distance of -0.93% [1] Detailed Stock Performance - Key stock performances include: - Songjing Co., Ltd. (688157): Today's change is -0.67% with a latest price of 40.09 yuan, which is -3.28% from the 10-day moving average [1] - Chunguang Technology (603657): Today's change is -3.47% with a latest price of 38.70 yuan, which is -6.79% from the 10-day moving average [1] - Pilin Bio (000403): Today's change is -0.52% with a latest price of 17.32 yuan, which is -2.64% from the 10-day moving average [1] Additional Stocks with Notable Changes - Other stocks showing significant changes include: - Jiangsu New Energy (603693): Today's change is -1.38% with a latest price of 12.87 yuan, which is -2.29% from the 10-day moving average [2] - Yongan Pharmaceutical (002365): Today's change is -1.04% with a latest price of 18.11 yuan, which is -1.45% from the 10-day moving average [2] - Mosi Co., Ltd. (001323): Today's change is -1.95% with a latest price of 28.16 yuan, which is -2.96% from the 10-day moving average [2]

Core Points - The announcement details the listing of 6,606,000 restricted shares of Aorite Pharmaceutical Co., Ltd. on September 22, 2025, following the expiration of a 60-month lock-up period [2][3][12] - The total share capital of the company after the initial public offering (IPO) is 406,195,234 shares, with 1.63% of this being the newly listed restricted shares [4][6][8] Group 1: Listing Details - The type of stock being listed is the initial public offering (IPO) shares, with a total of 6,606,000 shares available for trading [2] - The listing date for the restricted shares is set for September 22, 2025 [3][13] Group 2: Share Capital Changes - The company initially issued 41,000,000 shares during its IPO, resulting in a total share capital of 401,000,000 shares, which includes 41,000,000 unrestricted shares and 360,000,000 restricted shares [4][5] - The total share capital increased to 406,195,234 shares due to the issuance of 5,195,000 restricted shares under the 2022 incentive plan and the conversion of 234 shares from convertible bonds [6][8] Group 3: Lock-up Commitments - The shareholder, Tiantai Boren Investment Management Partnership, has committed to a lock-up period of 60 months for the shares prior to the IPO and has adhered to this commitment [9][11] - The shareholder's commitment includes conditions for share reduction and penalties for non-compliance, ensuring transparency and accountability [9]

证券代码：605116 证券简称：奥锐特 公告编号：2025-066 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 6,606,000股。 本次股票上市流通总数为6,606,000股。 本次股票上市流通日期为2025 年 9 月 22 日。 一、本次限售股上市类型 经中国证券监督管理委员会出具的《关于核准奥锐特药业股份有限公司首次 公开发行股票的批复》（监许可[2020]1969 号文）核准，奥锐特药业股份有限公司 （以下简称"奥锐特"或"公司"）首次向社会公众公开发行人民币普通股（A 股） 股票 41,000,000 股，并于 2020 年 9 月 21 日在上海证券交易所挂牌上市。公司首 次公开发行后总股本 401,000,000 股，其中无限售条件流通股为 41,000,000 股， 有限售条件流通股为 360,000,000 股 ...

国泰海通证券股份有限公司 关于奥锐特药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）向不特定对象发行 可转换公司债券及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关法律法规及规范性文件的规定，对奥锐特首次公开 发行部分限售股上市流通的事项进行了核查，具体情况如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会出具的《关于核准奥锐特药业股份有限公司首次 公开发行股票的批复》（监许可[2020]1969 号文）核准，奥锐特药业股份有限公 司首次向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，并于 2020 年 9 月 21 日在上海证券交易所挂牌上市。公司首次公开发行后总股本 401,000,000 股，其中无限售条件流通股为 41,000,000 股，有限售条件流通股为 360,000,000 股。 本次上市流通的限售股为公司首次公开发 ...

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Group 1: Macro Economic Insights - The recent appreciation of the RMB against the USD may be seen as a "catch-up" due to a weaker dollar environment, with the RMB appreciating by approximately 2.3% compared to a 10% depreciation of the dollar index in the first eight months of 2025 [5][6][7] - The domestic equity market's recovery and dovish signals from the Federal Reserve are key triggers for the recent rise in the RMB exchange rate, despite weaker manufacturing PMI data [6][8] - The RMB is expected to continue appreciating, but short-term fluctuations may occur due to uncertainties in global economic policies, particularly in Japan [8][9] Group 2: ETF Market Dynamics - Since June, non-broad-based ETFs have seen rapid growth, with net inflows reaching 227.9 billion RMB, indicating a shift in retail investor preferences towards ETFs [11][12] - Broad-based ETFs have experienced significant net redemptions, suggesting that while overall ETF inflows may appear modest, retail funds are actively entering the market through non-broad-based ETFs [12][13] - The current bull market is characterized by a shift from actively managed funds to ETFs, driven by factors such as product variety, cost efficiency, and ease of access [13][14] Group 3: Power Equipment and New Energy Sector - The photovoltaic industry is facing severe overcapacity, with nominal production capacity exceeding 1200 GW, leading to significant price declines across the supply chain [18][19] - Recent government initiatives aim to curb internal competition and stabilize the market, with signs of price recovery in the polysilicon segment [19][20] - Despite ongoing losses in the main supply chain, specialized companies are performing better than integrated firms, indicating a potential for recovery as supply-demand dynamics improve [20][21] Group 4: Chemical Industry Performance - The chemical raw materials and products manufacturing sector reported a revenue of 4.46359 trillion RMB in H1 2025, a year-on-year increase of 1.4%, but profits fell by 9% to 181.46 billion RMB [23][24] - The basic chemical industry achieved a revenue of 1.1707 trillion RMB in H1 2025, with a profit of 73.17 billion RMB, reflecting a 3.5% revenue increase year-on-year [24][25] - The petrochemical sector, excluding major state-owned enterprises, saw a revenue decline of 7.3% in H1 2025, indicating challenges in profitability [25][26] Group 5: Pharmaceutical Sector Developments - Sunshine Nuohuo (688621.SH) reported a revenue of 590 million RMB in H1 2025, a 4.87% increase, with a significant Q2 performance showing a 15.73% year-on-year growth [28][29] - The company is advancing its innovative drug pipeline, with multiple projects in clinical trials, indicating a strong growth trajectory [29][30] - Haofan Bio (301393.SZ) achieved a revenue of 270 million RMB in H1 2025, reflecting a 20.10% increase, driven by strong demand for GLP-1 drugs [32][33] Group 6: Food and Beverage Sector Insights - Shanxi Fenjiu (600809.SH) reported a revenue of 23.96 billion RMB in H1 2025, a 5.4% increase, but faced pressure on profit margins due to changing consumer preferences [40][41] - Wuliangye (000858.SZ) achieved a revenue of 52.77 billion RMB in H1 2025, a 4.2% increase, but is navigating challenges in maintaining price stability amid competitive pressures [45][46]